TRACON Pharmaceuticals Announces $8.8 Million Registered Direct Offering
TRACON Pharmaceuticals Announces $8.8 Million Registered Direct Offering SAN DIEGO, Dec. 22, 2020 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that it has entered into a securities purchase agreement with new and existing investors to sell an aggregate of 1.1 milli...